Alessandro M. Vannucchi

Research interests

Publications

• International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

  Blood · 2022 · https://doi.org/10.1182/blood.2022015850

• Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0077-1

• Classification and Personalized Prognosis in Myeloproliferative Neoplasms

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1716614

• The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

  Blood Cancer Journal · 2018 · https://doi.org/10.1038/s41408-018-0054-y

• A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.169

• MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.76.4886

• Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2017 · https://doi.org/10.1016/s2352-3026(17)30237-5

• Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

  The Lancet Haematology · 2017 · https://doi.org/10.1016/s2352-3026(17)30088-1

• Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

  Leukemia · 2016 · https://doi.org/10.1038/leu.2016.148

• Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

  Blood Cancer Journal · 2015 · https://doi.org/10.1038/bcj.2015.94

• Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.233

• Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

  Blood · 2014 · https://doi.org/10.1182/blood-2014-05-579136

• Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

  Blood · 2013 · https://doi.org/10.1182/blood-2013-02-485888

• Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1312542

• Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

  Blood · 2013 · https://doi.org/10.1182/blood-2013-03-488098

• Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

  Blood · 2013 · https://doi.org/10.1182/blood-2013-01-478891

• Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.163

• Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.42.3863

• Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

  Blood · 2012 · https://doi.org/10.1182/blood-2012-07-444067

• JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1110556

• A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

  Blood · 2012 · https://doi.org/10.1182/blood-2012-01-403279

• Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.34.5298

• Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

  Blood · 2011 · https://doi.org/10.1182/blood-2011-02-339002

• The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

  Blood · 2011 · https://doi.org/10.1182/blood-2011-01-328955

• Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.8436

• Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

  Blood · 2009 · https://doi.org/10.1182/blood-2008-09-176818

• A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

  Blood · 2009 · https://doi.org/10.1182/blood-2009-09-245837

• Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

  Blood · 2009 · https://doi.org/10.1182/blood-2009-04-216044

• Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

  Blood · 2008 · https://doi.org/10.1182/blood-2008-01-135897

• New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

  Blood · 2008 · https://doi.org/10.1182/blood-2008-07-170449

• Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden

  Leukemia · 2007 · https://doi.org/10.1038/sj.leu.2404854

• Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

  Blood · 2007 · https://doi.org/10.1182/blood-2006-12-064287

• Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

  Blood · 2007 · https://doi.org/10.1182/blood-2007-04-083501

Current projects

No projects listed.